Welcome to the Pharmacokinetics Research Group

 

Pharmacokinetics is the quantitative assessment of what the body does to a chemical following exposure. The fate of a chemical in a living organism is a function of its physical-chemical properties as well as the anatomy and physiology of the organism. Four main concepts form the basis for describing the rate and extent of exposure. These are Absorption, Distribution, Metabolism and Excretion, or ADME for short.

Our research is focused on building virtual organisms to study the pharmacokinetics of drugs and environmental contaminants. Physiologically-based pharmacokinetic (PBPK) models provide a mechanistic means of understanding how changes in anatomy and physiology can affect the ADME of a chemical. PBPK models are predictive and can be used to scale pharmacokinetics across species (e.g., rat to human) and within a species (e.g., healthy adult humans to children or patients) with an eye towards determining the right dose (in medicine) or determining differential risks associated with contaminant exposure (in human health risk assessment).

This research lab is also the population pharmacokinetic modelling lead within the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo.org) program. This program, initiated out of McMaster University by Dr. Alfonso Iorio, provides hemophilia treaters with a platform that, when given patient covariates and factor concentrate plasma levels, uses previously developed brand-specific population PK model and Bayesian forecasting to generate estimates of patient PK that can be used to optimize dosing in the individual. We have over 420 clinical sites using the WAPPS-Hemo service from over 30 countries. 

This website will provide you with further details of our current and future pharmacokinetic research. Peruse the list of publications and courses that I teach and email me if you have questions about the research or the website.


Students interested in graduate studies at either the M.Sc. or Ph.D. level with interests or experience in the following areas:

  • PBPK modeling
  • Pediatric PBPK modeling
  • PK/PD modeling

 can email me directly:  aedginto@uwaterloo.ca

I am particularly interested in students who possess strong mathematical and/or statistical skills.

  1. Feb. 22, 2021New Manuscript Publication

    Congratulations Jacky for the publication of your manuscript 'Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study' in the Haemophilia Journal.  

  2. Feb. 18, 2021Congratulations Jacky Yu

    Congratulations to Jacky for being the School of Pharmacy's nominee for the AFPC / CCPE Graduate Research Paper Award for his paper: A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients

  3. July 27, 2020Congratulations Team

    Congratulations to Paul Malik, Cindy Yeung, Shams Ismaeil, Urooj Advani, Sebastian Djie (Some of our PharmD 401 students who participated in the Winter 2020 term) for the acceptance of the article A Physiological Approach to Pharmacokinetics in Chronic Kidney Disease in the The Journal of Clinical Pharmacology.   Great work!


     

Read all news

Meet our people

Andrea Edginton

Dr. Andrea Edginton

Associate Professor

Dr. Edginton’s research focuses on improving the confidence of physiologically-based pharmacokinetic (PBPK) model outcomes through understanding model inputs and developing modeling workflows.